Literature DB >> 19106428

Update of the Drug Resistance Mutations in HIV-1.

Victoria A Johnson1, Francoise Brun-Vezinet, Bonaventura Clotet, Huldrych F Gunthard, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Douglas D Richman.   

Abstract

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.This December 2008 version of the IAS-USA drug resistance mutations figures updates those published in this journal in March/April 2008 (Johnson VA, Brun-Vezinet F, Clotet B, et al, Top HIV Med, 2008;16:62-68). The compilation includes mutations that may contribute to a reduced virologic response to HIV-1 drugs. It should not be assumed that the list presented here is exhaustive. Drugs that have been approved by the US Food and Drug Administration (US FDA) as well as any drugs available in expanded access programs are included and listed in alphabetical order by drug class. The figures are designed for practitioners to use in identifying key mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19106428

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  78 in total

1.  Computational analysis of HIV-1 protease protein binding pockets.

Authors:  Gene M Ko; A Srinivas Reddy; Sunil Kumar; Barbara A Bailey; Rajni Garg
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

2.  Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.

Authors:  Ying Chuan Lin; Alexander L Perryman; Arthur J Olson; Bruce E Torbett; John H Elder; C David Stout
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-05-12

3.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

4.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

5.  Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.

Authors:  Annie Talbot; Philip Grant; Jonathan Taylor; Jean-Guy Baril; Tommy Fulisma Liu; Hugues Charest; Bluma Brenner; Michel Roger; Robert Shafer; Régis Cantin; Andrew Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

6.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

7.  Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Authors:  Rajin Shahriar; Soo-Yon Rhee; Tommy F Liu; W Jeffrey Fessel; Anthony Scarsella; William Towner; Susan P Holmes; Andrew R Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

8.  Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.

Authors:  M C Hosseinipour; J J Kumwenda; R Weigel; L B Brown; D Mzinganjira; B Mhango; J J Eron; S Phiri; J J van Oosterhout
Journal:  HIV Med       Date:  2010-03-19       Impact factor: 3.180

9.  N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.

Authors:  Nicolas Sluis-Cremer; Katie Moore; Jessica Radzio; Secondo Sonza; Gilda Tachedjian
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

10.  Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Authors:  Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.